[(2E)-cyclooct-2-en-1-yl] N-ethylcarbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(2E)-cyclooct-2-en-1-yl] N-ethylcarbamate
• 化学式: C₁₁H₁₉NO₂
• 分子量: 197.27
• InChiKey: XZQMZNUDLQUAAO-SOFGYWHQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] CHEMICALLY CLEAVABLE GROUP<br/>[FR] GROUPE CLIVABLE PAR VOIE CHIMIQUE
  申请人：TAGWORKS PHARMACEUTICALS B V

  公开号：WO2014081303A1

  公开（公告）日：2014-05-30

  Disclosed is the use of the reactive components of the inverse electron-demand Diels Alder reaction for chemical masking and unmasking in vitro. This can be applied in complex chemical reactions and, particularly in the synthesis of biomolecules, e.g. on solid supports. The reactice components are a dienophile, particularly a trans-cyclooctene, and a diene, particularly a tetrazine.

  本文揭示了逆电子需求Diels-Alder反应的反应性组分用于体外化学掩蔽和解除掩蔽。这可以应用于复杂的化学反应中，特别是在生物分子合成中，例如在固相支持上。反应性组分包括双烯，特别是反式环辛二烯，和二烯，特别是四氮唑。
• [EN] BIO-ORTHOGONAL DRUG ACTIVATION<br/>[FR] ACTIVATION DE MÉDICAMENT BIO-ORTHOGONALE
  申请人：TAGWORKS PHARMACEUTICALS B V

  公开号：WO2014081301A1

  公开（公告）日：2014-05-30

  Disclosed is a kit for the administration and activation of a Prodrug. The kit comprises a Masking Moiety linked, directly or indirectly, to a Trigger moiety, which in turn is linked to a Drug, and an Activator for the Trigger moiety. The Trigger moiety comprises a dienophile and the Activator comprises a diene, whereby the dienophile is an eight-membered non- aromatic cyclic alkenylene group, preferably a cyclooctene group, and more preferably a trans-cyclooctene group. The Trigger and the Activator undergo a fast, bio-orthogonal reaction resulting in the release of the Masking Moiety, and activation of the drug.

  揭示了一种用于给予和激活前药的工具包。该工具包包括一个掩蔽基团，直接或间接地连接到一个触发基团，该触发基团又连接到一种药物，以及一个用于触发基团的激活剂。触发基团包括一个二烯烃，激活剂包括一个二烯，其中二烯烃是一个八元非芳香环烯基团，优选为环辛烯基团，更优选为反式环辛烯基团。触发基团和激活剂经历一个快速的生物正交反应，导致掩蔽基团的释放和药物的激活。
• TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS
  申请人：The Regents of the University of California

  公开号：US20170087258A1

  公开（公告）日：2017-03-30

  The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.

  本发明提供了一种方法，通过将生物相容性固体支撑物植入患者并与第一结合剂连接，以及将与治疗或诊断剂连接的第二结合剂注入患者，从而实现对靶器官或组织的选择性输送治疗或诊断剂，使治疗或诊断剂在靶器官或组织中积累。